Public-Private Interface: Evotec's growing Ivy 


Table 1. Evotec's partnerships with universities and research organizations. Evotec AG's Open Innovation Alliance with Yale University is among the few drug discovery and development partnerships it has with a university or research organization. The biotech already has ongoing partnerships with more than 10 pharmas.

Source: BioCentury Archives


Disease area




Yale University


Open Innovation Alliance to jointly assess and develop technologies from the university into late preclinical and IND-ready assets that could be licensed to pharma

Project selection

January 2013

Brigham and Women's Hospital/Harvard University

Renal damage/renal disease

CureNephron collaboration to jointly discover biomarkers implicated in kidney damage and develop therapies against kidney disease

Preclinical testing

January 2012

Harvard/Howard Hughes Medical Institute/Johnson & Johnson (NYSE:JNJ)


CureBeta collaboration to jointly discover and develop therapies that target pancreatic b cell regeneration

Preclinical testing; portfolio of small molecules and biologics licensed to J&J's Janssen Pharmaceuticals Inc. unit

March 2011 (Harvard/HHMI); July 2012 (J&J)

CHDI Foundation Inc.

Huntington's disease

Strategic partnership to provide the foundation with medicinal chemistry, assay development, screening and library synthesis services

Not applicable

August 2006; third deal extension in October 2012